Published in Blood Weekly, April 28th, 2005
According to recent research published in the journal Haemophilia, "the goal of all hemophilia therapy is to prevent bleeding and its associated complications. Replacement by factor concentrates can only ever be suboptimum, and efforts are being made to correct the genetic cause of the disorder. Hemophilia is an ideal candidate for gene therapy, as it is caused by mutations in a single gene."
"A number of vectors have been used in an attempt to obtain therapeutic...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Blood Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.